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Raf-1 Kinase Inhibitor Protein Regulates Cell
Migration and Proliferation of Mouse Embryonic
Fibroblasts

Donghui Song, B.S.
University of Connecticut, 2012
Raf-1 kinase inhibitor protein (RKIP) is a multifunctional protein that plays a
regulatory role in a variety of biological activities, including cellular signaling
pathways, cell proliferation, cell migration, cell cycle, apoptosis and cancer
metastasis. In our previous study, we have identified that RKIP has a positive
effect on the cell migration in Madin-Darby canine kidney (MDCK) cell line.
Moreover, we also discovered that a small stretch of amino acids (146RGKFKVASRFKK-157) as the nuclear localization signal (NLS) targets RKIP
for translocation to the nucleus. In this study, we showed strong evidence that
RKIP expression has no effect on cell migration in both wild type mouse
embryonic fibroblasts (MEF), and MEF cells lacking the RKIP gene (MEF RKIP
-/-

) with RKIP reintroduced. Furthermore, we found that RKIP expression inhibits

the cell proliferation of the MEF cell line. Furthermore, we found that the nuclear
localization of RKIP has a regulatory role in cell migration, cell proliferation and
cell cycle distributions. Interestingly, we have also determined the effects that
RKIP has on cell migration, cell proliferation and cell cycle distribution are
independent of MAPK/ERK activation suggesting the involvement of a different
pathway.
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CHAPTER I
INTRODUCTION TO RAF-1 KINASE INHIBITOR PROTEIN AND ITS
BIOLOGICAL FUNCTIONS
1.1 An overview of Raf-1 kinase inhibitor protein
Raf-1 kinase inhibitor protein (RKIP), a 21 kDa protein with 187 amino acids, has been
discovered as a member of the phosphatidylethanolamine binding protein (PEBP) family
[1, 2]. Initially, the name of this protein was phosphatidylethanolamine binding protein 1
(PEBP1) resulting from its ability to bind weakly with phosphatidylethanolamine [3].
With the further study on it, this protein was renamed as Raf-1 kinase inhibitor protein
(RKIP), because it was found that RKIP can bind to Raf kinase and inhibit the interaction
between Raf-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase
1 (MAPK/ERK) [4].
RKIP is commonly seen in the brain, testis, liver and kidney of mammalian animals [5, 6].
As well as the other PEBP family proteins, it has been determined from the 3D X-ray
crystal structure of RKIP that there are two main domains, ligand binding pocket and
globular structure [7, 8] (Figure 1). It has been reported that the ligand binding pocket
provides the binding site not only for phosphatidylethanolamine, but also for the newly
discovered small molecule inhibitor locostatin [9]. However, the mechanism of binding
between RKIP and its ligands, as well as the specific amino acid binding sites has not as
of yet been identified. Furthermore, the globular structure domain also plays a key role in
a multitude of biological functions, due to its globular surface being able to provide
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enough surface area for association with various cellular function modulator proteins. For
example, previous studies have shown that RKIP is able to interact with several proteins
that function as cellular signaling pathway regulators, such as Raf-1, B-Raf,
MAPK/extracellular signal regulated kinase kinase (MEK), G protein coupled receptor
kinase 2 (GRK2), and nuclear factor κB (NF-κB)-inducing kinase (NIK), transforming
growth factor (TGF)-β activated kinase 1 (TAK1), inhibitor of κB kinase α (IKKα) and β
(IKKβ) [4, 10-15]. Although the binding sites of RKIP and most of the proteins described
above have not been revealed, a critical residue (Ser153) on RKIP was identified to have
the relationship with the interaction between RKIP and Raf-1 [10]. The evidence has
shown that RKIP is phosphorylated at Ser153. Further studies have shown that the
phosphorylation at Ser153 has a crucial role in the regulation of the interaction between
RKIP and Raf-1. Protein kinase C (PKC) phosphorylates the Ser153 residue leading to
the dissociation of the RKIP-Raf-1 complex. It has been assumed that the steric hindrance
contributes more to the dissociation than electrostatic repulsion [10]. Nevertheless, this is
not the end of this story of the relationship between the structure of RKIP and its
biological function. There are still many questions, such as the number and location of
binding sites corresponding to different binding partners that has yet to be determined, so
that a better understanding of this regulatory protein may be obtained.

2

Figure 1 3D X-ray crystal structure of Raf-1 kinase inhibitor protein (RKIP). The ligand
binding pocket domain is shown in red. The globular structure domain is shown in blue.
The phosphorylation site Ser153 residue is shown in green. The figure is referred from
Expert Opin. Ther. Targets (2008) 12(10): 1275-1287.
1.2 Biological functions of Raf-1 Kinase Inhibitor Protein
1.2.1 Role of RKIP in the regulation of signaling pathway
1.2.1.1 Regulation of Raf-1 signaling pathway
Numerous experimental findings have revealed the fact that numerous biological
activities, including cell proliferation, cell survival and cell differentiation, are mediated
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by the Raf-1/MEK/ERK pathway in which RKIP plays a critical role in modulating the
aforementioned cell functions [16-22].
Presented in this thesis is how the Raf-1/MEK/ERK pathway functions at the molecular
level (Figure 2). Initially, the stimulus from the environment is sensed at the growth
factor cytokine. The signal is propagated by various growth factors, such as epidermal
growth factor (EGF), platelet-derived growth factor (PDGF) and nerve growth factor
(NGF). Afterwards, the receptor tyrosine kinase (RTK) is activated via phosphorylation
on its tyrosine residue. RTK acts as an initiator for many signaling cascades including
Raf-1/MEK/ERK and NF-κB signaling cascades [16, 17]. Then RTK activates Ras [23],
a small protein which belongs to G protein family, through a number of growth factor
receptor proteins. The growth factor receptor-bound protein 2 (Grb-2) and its domain, son
of sevenless (SOS), are also involved in this Ras activation process. SOS on Grb-2
interacts with Ras through its GTP exchange factor (GEF) domain, where GDP is
phosphorylated to GTP [23-25]. After Ras is activated, it binds with Raf-1 kinase and
activates it [26]. Subsequently, activated Raf-1 phosphorylates and activates
MAPK/extracellular signal regulated kinase kinase (MEK) directly. In the same way,
MEK then activates extracellular signal-regulated kinase (ERK) by phosphorylation [27].
To our knowledge, the Raf-1/MEK/ERK signaling pathway has a crucial function in the
modulation of the gene expression. In the nucleus of the cell, phosphorylated ERK
converts Fos proteins to Fos phosphoproteins [28]. When phosphorylated Fos proteins
bind with the transcription factor activation protein 1 (AP-1), AP-1 is then activated and
associates with the 12-O-tetradecanoyl phorbol-13-acetate (TPA) response element (TRE)
[29- 32]. As a result, the stimuli from the environment affect gene expression leading to
4

the modulation of biological activities. For example, when the signal impacts Bcl-2 gene
expression through Raf-1/MEK/ERK signaling pathway, the cell apoptosis is modulated
accordingly [33-35]. In other words, Bcl-2 is able to regulate cell. Moreover, besides Bcl2, many more genes including cyclin-dependent kinases (CDKs), Bcl-xL and Mcl-1 are
also involved in the signaling pathway to regulate some certain biological process, such
as cell proliferation, apoptosis, differentiation and migration [36-38]. Thus, disruption of
any part of the Raf-1/MEK/ERK signaling pathway will lead to a deleterious effect in the
behavior of the cell resulting in many human diseases such as cancer.
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Figure 2 The Raf-1/ MEK/ERK signaling pathway. This signaling pathway plays a key
role in transferring signal from cell membrane to the nucleus, leading the AP-1
transcription. The main direction of the signal transduction can be described like this:
RTKGrb-2RasRaf-1MEKERKAP-1gene expression. The figure is
referred from Adv Cancer Res (2004) 91: 169-200.
After the discovery of the Raf-1/MEK/ERK signaling cascade, the regulation process has
remained complex and difficult to understand until Kam Yeung et al. identified RKIP as
an inhibitor of this signaling pathway [4]. As we know, Raf-1 associates with MEK and
activates it by phosphorylation. Experimental results have shown that overexpression of
RKIP decreases the efficiency of the signaling pathway by disrupting the association
between Raf-1 and MEK. Subsequently, the phosphorylation of MEK is inhibited, so that
ERK cannot be phosphorylated and activated by MEK. As such, the signal stops at the
Raf-1-MEK complex and thus cannot be transferred to MEK. As a consequence, RKIP is
discovered as having an inhibitory function on Raf-1/MEK/ERK cascade. A model has
been made to explain the mechanism of the RKIP inhibitory function. RKIP is considered
as a competitive inhibitor of the association between Raf-1 and MEK (Figure 3). The
result from binding site mappings among RKIP, Raf-1 and MEK definitely proves this
conclusion [14]. It is well known that RKIP is able to bind physically with both Raf-1
and MEK. It leads to the disruption of their association and prevents phosphorylation of
MEK. Additional data was also found to provide more evidence for this mechanism. In
vitro, it was identified that mitogens can down-regulate the association of RKIP and Raf1. Interestingly, the signaling pathway is recovered through the negative regulation with
mitogens. Thus, we believe that the molecular mechanism model shown in Figure 3 best
6

elucidates the role that RKIP plays in the inhibition of Raf-1/MEK/ERK signaling
pathway.

Figure 3 A proposed mechanism of inhibition of the Raf-1/MEK/ERK signaling pathway
by RKIP. The signal propagates only when the Raf-1 binds to MEK and activates it by
phosphorylation. Overexpressed RKIP disrupts the association between Raf-1 and MEK.
Then no signal comes out with the suppression function by RKIP. However, he signal is
dramatically enhanced when the mitogens is used to dissociate the Raf-1-RKIP complex.
Therefore, both of the experimental result described above shows that RKIP plays a role
in reducing the signal in the pathway. The figure is referred from Mol. Cell. Bio. 2008
20(9): 3079-3085.
In addition to the inhibitory function by RKIP, recent studies show that Raf-1/MEK/ERK
signaling pathway can be positively regulated by protein kinase C (PKC) [10, 39] (Figure
4). The PKC is a form of serine/threonine kinase that mediate the Raf-1 cascade by
phosphorylating RKIP. It is already known that G protein coupled receptors (GPCRs)
induce the PKC phosphorylation of the Serine 153 residue on RKIP when the cell is
7

stimulated. The phosphorylation on Ser153 leads to the dissociation of the Raf-1-RKIP
complex possibly due to steric hindrance. As a consequence, the PKC prevents the
suppression of Raf-1 cascade by RKIP. We also know that the PKC functions not only as
an activator for Raf-1 [40-42], but also as an activator for MEK for the reason that they
can phosphorylate MEK as well [43]. Thus, the PKC can be considered as an upregulator for the Raf-1/MEK/ERK signaling pathway. However, the mechanism that the
down-regulation by RKIP and up-regulation by PKC work coordinately to mediate the
physiological process in the cell is still unclear. In that, we still do not know when the
positive mediation is dominant, or under what conditions the negative modulation
displays more apparently.

Figure 4 Raf-1 signaling pathway is regulated by both RKIP and PKC. By binding to
Raf-1 and MEK, RKIP prevents the Raf-1 binding with and phosphorylating MEK. Here
RKIP is considered as a downstream suppressor. By phosphorylating the Serine 153
residue on RKIP, PKC induces the dissociation between Raf-1 and MEK, which in turn
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acts as an upstream activator. The figure is referred from Molecular Cell Biology (2005)
6: 827-837.
Although this signaling cascade was mapped years ago and a great progress has been
made in the study on it, there are still many unsolved problems on the modulation of Raf1/MEK/ERK signaling pathway including what other specific proteins besides RKIP
participate in regulation, the mechanism of modulation, what are the binding sites
between the regulator proteins and their binding partners involved in the pathway and the
timing of phosphorylation and de-phosphorylation of the kinases in the cascades.
1.2.1.2 Regulation of NF-κB signaling pathway
Similar to the Raf-1 signaling pathway, the NF-κB pathway is also characterized as a key
modulator for many physiological functions, including cell growth, cell apoptosis, cell
adhesion and immunity [44-50]. Errors in the NF-κB pathway are found to be responsible
for cancer, inflammation, neurological disease, and improper immune development [5155]. RKIP participates in not only the regulation of Raf-1 cascade we introduced above,
but also that of NF-κB signaling pathway. Moreover, RKIP is reported to have an
inhibitory function on NF-κB pathway [56].
The transcriptional activator nuclear factor kappa B (NF-κB) is a form of REL family
dimeric protein [57] which is essential for regulating gene expression which is
responsible for cell proliferation, survival, adhesion and immunity. Recent studies have
revealed that gene expression related to NF-κB is activated by several kinds of stimuli,
such as stress and inflammation [58]. Based on the fact that proinflammatory cytokines
interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) are activators for the
9

NF-κB signaling pathway [59, 60], they stimulate the transforming growth factor βactivated kinase 1 (TAK-1) and NF-κB-inducing kinase (NIK) upon binding with tumor
necrosis factor receptor 1 (TNF-R1) [24]. Afterwards, as the signal continues to be
propagated when the TAK-1 and NIK activate by phosphorylating the IκB (inhibitor of
NF-κB) kinase (IKK) which contains two subunits IKKα and IKKβ [61-70].
Subsequently, IKK activates and phosphorylates IκB, afterwards phosphorylated IκB is
degraded by 26S proteasome. As a consequence, the phosphorylation and degradation of
IκB causes the NF-κB to depart from the IκB-NF-κB complex. Finally, upon dissociation
with IκB, NF-κB translocate to the nucleus and regulate the gene expression that
responds to the NF-κB signaling pathway [71] (Figure 5).
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Figure 5 The NF-κB signaling pathway. The NF-κB cascade is initiated by TNF-α which
acts

as

a

signal

activator.

The

signal

is

propagated

as

follows:

TAK-

1/NIKIKKα/βIκB/NF-κB NF-κBgene expression in nucleus. The figure is
referred from Adv Cancer Res (2004) 91: 169-200.
Kam Yeung et al. demonstrated that RKIP can modulate the NF-κB signaling pathway,
as well as the Raf-1 signaling pathway [56]. It is significant that RKIP is able to regulate
two different pathways which are independent of each other. In their study, RKIP is
discovered as an inhibitor of NF-κB release so that it down-regulates the NF-κB signaling
pathway. Although the detailed mechanism of the inhibitory function by RKIP still
remains unknown, what we can recognize is that RKIP can prevent the phosphorylation
of IKKα and IKKβ by associating with TAK-1 and NIK. It is very similar with
mechanism that RKIP negatively regulates the Raf-1 cascade by interacting with Raf-1
and MEK, which blocks the phosphorylation and activation of MEK. Furthermore,
another model was built to show that RKIP can also interact with IKKα and IKKβ [72].
This interaction leads to the blocking of the phosphorylation on IκB, so that IκB cannot
be degraded and NF-κB cannot be released to regulate the gene expression. Taken
together, RKIP is found to interact with four important kinases involved in the NF-κB
signaling pathway, including TAK-1, NIK, IKKα and IKKβ, which cause the
deactivation of NF-κB. Therefore, RKIP here acts as a down-regulator for the NF-κB
cascade.
1.2.1.3 Regulation of GPCR signaling pathway
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Previous studies have revealed that GPCR is yet another important signaling pathway
which serves as a modulator for a variety of biological processes, including inflammation,
hormone and blood pressure regulation [73]. As it is shown in the Raf-1 pathway, PKC
phosphorylates RKIP on it Serine 153 site and leads to the dissociation of Raf-1-RKIP
complex. Then the phosphorylated RKIP departs from Raf-1 and bind to G protein
coupled receptor kinase 2 (GRK-2), which is a suppressor for the stimulation of G protein
coupled receptors (GPCRs) through their phosphorylating [10, 11, 74], leading to the loss
of inhibitory activity of GRK-2. As a result, the GPCR signaling pathway is promoted
because the deactivation of GRK-2 by the PKC-mediated phosphorylation of RKIP
(Figure 6). Therefore, RKIP we report here works as a positive modulator for this
pathway.
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Figure 6 An overview scheme for the role of RKIP in Raf-1, G protein coupled receptor
(GPCR) and NF-κB signaling pathways. The figure is referred from Expert Opin. Ther.
Targets (2008) 12(10): 1275-1287.
1.2.2 Role of RKIP in cell cycle
Cell cycle, which is also called cell-division cycle, is a series of events involved in the
cell division process. In the eukaryotes cells, a cell cycle starts at a resting phase (G0
phase) during which the cell has left the previous cycle and is ready for the next cycle.
Then the next step of a cell cycle is interphase including G1, S and G2 phase, during
which the cell keeps growing, replicates its DNA and gets everything ready for its final
step – mitosis phase. In the mitosis phase (M phase), the cell stops growing and it is
eventually orderly divided to two daughter cells [75, 76].
Many recent studies on the relationship between RKIP and the cell cycle have
demonstrated that RKIP does play a key role in cell cycle regulation. Like the other
physiological processes, cell cycle is also modulated by multiple signaling pathways.
Raf-1/MEK/ERK as discussed above is reported to be one of the signaling cascades that
function as a modulator of cell cycle [77]. The cell cycle is ended at mitosis phase during
which a spindle checkpoint is formed in the middle of the mitosis [78, 79]. The spindle
checkpoint is considered to be a monitor for making sure the kinetochore is attached to
the correct position of the chromosomes, so that all replicated chromosomes can be
divided equally and orderly to the two daughter cells. As a consequence, it is obvious that
genomic stability is determined by the formation of this spindle checkpoint. Recent
reports have revealed that RKIP is able to modulate the formation of the checkpoint by
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inhibiting Aurora B kinase [80] (Figure 7). As it was mentioned previously, RKIP
inhibits the Raf-1 signaling pathway by interrupting the interaction between Raf-1 and
MEK. So it can be clearly seen that the depletion of RKIP leads to the hyper-activation of
Raf-1 cascade, which is found to be a reason for down-regulating the Aurora B kinase [81,
82]. The inhibition of Aurora B kinase by RKIP results in abnormal separation of the
chromosomes which may bring about cell apoptosis or even ontogenesis [83].
Furthermore, Al-Mulla et al. recently reported that depletion of RKIP in HEK 293 cells
enhances the rate of the cell proliferation [84]. The proposed mechanism is related to the
glycogen synthase kinase-3β (GSK3β) pathway. It has been shown that the GSK3β
inhibits the activation of cyclin D1, which plays an important role in cell cycle. RKIP is
known to act as a deactivator of GSK3β [85]. Thus, RKIP here works for stabilizing the
cyclin D1. The acceleration of cell proliferation can be well explained by this significant
finding. As with cyclin D1, there may be other gene regulatory proteins involved in cell
cycle that are modulated by RKIP [86-88]. In the case of RKIP silencing, it is apparent
that the expression and functions of these gene regulatory proteins are impacted. A
proposed explanation for the higher rate of cell proliferation is that the depletion of RKIP
induces some genes involved in interphase and mitosis phase abnormally expressed
which leads to the reduction of time in G1/S and G2/M phase transition.

14

Figure 7 Regulation of spindle checkpoint by RKIP. The formation of the checkpoint in
the cell cycle process is directly modulated by Aurora B kinase, which is effected by the
Raf-1/MEK/ERK signaling pathway. In the case when RKIP is depleted, the hyperactivation of the Raf-1 cascade inhibits Aurora B kinase, thereby leads to the abnormal
cell cycle. The figure is referred from Expert Opin. Ther. Targets (2008) 12(10): 12751287.
1.2.3 Role of RKIP in apoptosis
Apoptosis is known as a biological process of programmed cell death (PCD) which
usually takes place in multicellular organisms [89-91]. Compared with necrosis,
apoptosis is a normal biological activity which is considered as an advantageous
phenomenon in the life cycle [92]. For example, there are 50 – 70 billion cells die each
day due to apoptosis in a human adult [93]. As we know, apoptosis plays a critical role in
human health. Deregulation of cell apoptosis pathway may cause drug resistance. The
15

drug resistant cells may become cancer cells when they lose the apoptotic function [9496]. Nowadays, chemotherapeutic drugs or irradiation induced apoptosis has been widely
used as a therapeutic treatment of cancer.
As it was described in the role of RKIP in signaling pathway, there are two major
pathways that are able to regulate cell apoptosis by mediating the gene expression. They
are Raf-1 and NF-κB cascades. Since it is already known that RKIP inhibits both of these
two signaling pathways, it is very likely RKIP also has an effect on the regulation of cell
apoptosis (Figure 8). Recently, many studies have provided enough evidence for the role
of RKIP in cell apoptosis. In non-Hodgkin’s lymphoma B cells, RKIP expression is
induced by the chemotherapy drug which is called Rituximab [97]. Consequently,
induced expression of RKIP then inhibits the Raf-1 pathway and leads the cell death.
Moreover, in RKIP overexpressed prostate and melanoma cells, the cell apoptosis is
found to be regulated through NF-κB pathway [98]. Here, the apoptosis of the cells is
stimulated by death receptor ligands, such as tumor necrosis factor α (TNF-α), TNFrelated apoptosis-inducing ligand (TRAIL), and Fas ligand (FasL) [99]. Therefore, these
results clearly illustrate that RKIP functions as a modulator for cell apoptosis by
inhibiting either Raf-1 or NF-κB pathway.
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Figure 8 Model of RKIP up-regulating chemotherapy drug-induced cell apoptosis.
Chemotherapy drug-induced expression of RKIP promotes the cell apoptosis by
inhibiting Raf-1, NF-κB pathways or both simultaneously. The figure is referred from
Expert Opin. Ther. Targets (2008) 12(10): 1275-1287.
1.2.4 Role of RKIP in cancer metastasis
Cancer metastasis is defined as a cancer cells leaving the original tumor and colonizing
other tissues, forming secondary tumors and aggravating the disease [100, 101]. Thus,
research in cancer metastasis inhibition has becoming a pressing topic. Here we report the
function of RKIP in the regulation of tumor metastasis. RKIP was initially found to have
lower expression in C4-2B cells (a form of metastatic prostate cells) compared with its
expression in LNCaP (a form of nonmetastatic prostate carcinoma cells, the parental cells
of C4-2B cells) [102]. Moreover, reduced or nonexpression of RKIP was subsequently
17

discovered in other cancer or tumor cell lines, including breast cancer [103], colorectal
cancer [104-106], anaplastic thyroid cancer [107], hepatocellular carcinoma [108, 109],
insulinomas [110] and melanoma [12, 111]. In addition, there is no effect on the growth
of the primary tumor cells when the RKIP is overexpressed. The overexpression of RKIP
is only found to inhibit the tumor invasion. Therefore, these findings show that RKIP can
be regarded as a potential suppressor of cancer metastasis.
However, there is little known about the mechanism of the regulation of cancer
metastasis by RKIP. One proposed mechanism is that RKIP modulates the metastasis by
controlling the apoptotic pathway. The abrogation of the cell apoptosis process is one
aspect that leads to cancer. RKIP is discovered as an inhibitor of Raf-1 and NF-κB
signaling cascades which are responsible for cell apoptosis. In the tumor cells, the lack of
RKIP may cause the disruption of these two key signaling pathways. As a consequence,
the apoptotic signal is disrupted, so that the tumor cells with low RKIP levels show
resistance to apoptosis leading to their metastasis [112]. However, some recent reports
demonstrate the opposite opinion to the mechanism above. Their results have shown the
fact that knockdown of RKIP in Merkel cell does not affect the level of phosphorylation
of ERK [113]. Thus, it seems that the mechanism of how RKIP regulates metastasis is
still poorly understood. Much work is required to be done to get a definitive answer to
this problem.
1.2.5 Role of RKIP in cell migration
Cell migration is a multi-step process that involves dynamic assembly and disassembly of
cytoskeleton, attachment and detachment to extracellular proteins, and translocation of
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the cell, which plays a key role in many biological processes including embryonic
development, immune function, and wound healing [114]. Moreover, errors in cell
migration cause some diseased processes such as tumor formation, cancer cell invasion
and metastasis [115].
By now, the relationship between RKIP and cell migration is not clearly understood, due
to the conclusions made by different investigators are controversial. In our previous study,
Zhu et al. demonstrated that knockdown RKIP decreases the rate of cell migration of
Madin-Darby canine kidney (MDCK) epithelial cells. Moreover, they discovered a small
molecule inhibitor of RKIP, locostatin, inhibits the activity of RKIP by disrupting the
association between RKIP and Raf-1 [116]. Based on the function of locostatin, we
previously reported that the cell migration rate of RKIP overexpressed MDCK cell is
dramatically higher than that of normal MDCK cells. In addition to it, we also found cell
migration rate of RKIP overexpressed MDCK cell treated with locostatin is slower than
that of the control. Taken together, our previous study reveals that RKIP plays a positive
role in cell migration. However, opposite conclusion of the function of RKIP on cell
migration was made by other groups. They demonstrated that the overexpression of RKIP
leads to the decrease of the rate of cell migration in other cells, such as hepatoma and
malenoma cell lines [84, 109, 117]. These contradictory findings show that the effect
RKIP on cell migration is cell line dependent. The detailed mechanism for the role of
RKIP in cell migration requires further study.
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CHAPTER II
RAF-1 KINASE INHIBITOR PROTEIN NUCLEAR LOCALIZATION HAS A
REGULATORY EFFECT ON CELL MIGRATION AND PROLIFERATION
INDEPENDENT OF THE MAPK/ERK PATHWAY
2.1 Introduction
Raf-1 kinase inhibitor protein (RKIP) is a 21 kDa protein that was initially discovered as
a member of phosphatidylethanolamine-binding protein (PEBP) family and named
PEBP1, as it weakly binds to phophatidylethanolamine [118, 119]. PEBP1 was renamed
as RKIP since it was found to inhibit Raf-1 kinase. From numerous experimental results,
RKIP has been discovered as an essential protein in many signaling pathways. In the Raf1/MEK/ERK signaling pathway, RKIP binds to Raf-1 kinase [120, 121] and disrupts the
interaction between Raf-1 and mitogen-activated protein kinase/extracellular signalregulated kinase 1 (MAPK/ERK), thus preventing phosphorylation and activation of
MEK1 and results in the negative regulation of the Raf-1 signaling cascades [120, 121].
As we know, phosphorylation on the serine 153 residue of RKIP by Protein kinase C
(PKC) leads to dissociation between RKIP and Raf-1. This results in a new association
between RKIP and G protein-coupled receptor kinase 2 (GRK2) [122, 123]. In GPCR
signaling pathway, GRK2 phosphorylates G protein-coupled receptors (GPCRs) leading
to an internalization of the receptors and subsequent inhibition of their signaling activity
[123]. The association between RKIP and GRK2 results in the inactivation of GRK2
which leads to a positive regulation of GPCR signal receptor activation [123].
Furthermore, RKIP expression has also been found to antagonize the activation of the
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NF-B pathway [124, 125]. In the NF-B signaling pathway, RKIP was found to interact
with the following kinases involved in the NF-B cascade: transforming growth factor activated kinase 1 (TAK1) [124], nuclear factor B (NF-B)-inducing kinase (NIK)
[124], inhibitor of B kinase  (IKK) and  (IKK) [124]. To our knowledge, the
interaction between RKIP and the four kinases listed above is regarded as a supposed
mechanism of the down-regulation of NF-B signaling pathway by RKIP. Recently, it
was discovered that RKIP enhances GSK3 signaling by stabilizing GSK3 [126].
Interestingly, the aforementioned RKIP modulated signaling pathways have all been
shown to play a role in cell cycle progression [127-132]. However, the physiological role
of RKIP is not limited to cell proliferation. RKIP has also been associated with apoptosis
[133-136], cell adhesion [137], cell migration [128, 136-145], and as a tumor suppressor
in a wide variety of cancer cell types [127, 128, 133, 134, 141, 146-159]. These studies
suggest that the biological effects of RKIP are quite complex and cannot be elucidated by
one pathway.
In order to formulate a conceivable mechanism by which RKIP regulates biological
activities such as cell migration and proliferation, we have studied exhaustively on the
relationship between localization of RKIP to the nucleus and the biological activities
modulated by RKIP. To our knowledge, it has been reported that RKIP is able to
translocate in the nucleus [129, 130]. However, the mechanism of RKIP translocation
still remains unclear. So far, two mechanisms have been discovered as the pathways by
which the small size proteins are transported into the nucleus. Proteins with a molecular
mass is lower than 45 kDa are believed to translocate to the nucleus via passive diffusion.
Thus, the translocation mechanism of RKIP was believed to be by passive diffusion due
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to its limited size (For a review, see ref. [161]). For the proteins greater than 45kDa, the
transportation of the proteins from the cytoplasm to the nucleus depends on the importin
superfamily which is functions as transport proteins. In this translocation mechanism,
nuclear localization signal (NLS), which is a short stretch of amino acids on the protein
being transported. NLS plays a key role in the recognition between the target proteins and
importin. Proteins with NCL are initially recognized by a heterodimer importin α/β, then
translocated into the nucleus. In collaboration with Christian Argueta, we have previously
reported that a small stretch of amino acids (146-RGKFKVASRFKK-157) is the NLS
targets RKIP to the nucleus. Our experimental results demonstrated that the nuclear
localization signal (NLS) on RKIP binds to the nuclear transport protein importin  and
ultimately leads to nuclear translocation.
Based on the discovery of the nuclear localization signal on RKIP, we have done
considerable work to determine if there is any connection between the nuclear
localization of RKIP and cell migration and proliferation. Initially, we chose wild type
RKIP expressing mouse embryonic fibroblasts (MEF RKIP+/+) cells to conduct the
experiment. Interestingly, the mouse embryonic fibroblasts cells with green fluorescence
protein (GFP) labeled RKIP expressed (MEF RKIP+/+ + GFP-RKIP) have a slightly
higher rate of cell migration than wild type RKIP expressing mouse embryonic
fibroblasts (MEF RKIP+/+) cells. In addition to this result, we discovered that MEF
RKIP+/+ cells with NLS deficient mutants of RKIP expressed have a visibly slower rate of
cell migration than the wild type MEF RKIP +/+ cells. Therefore, we can draw a
conclusion that the nuclear localization of RKIP does have an obviously regulatory effect
on the cell migration of MEF cell line. Furthermore, we also worked on exploring if NLS
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has the same regulatory effect on cell proliferation. To our surprise, the cell proliferation
result fails to prove this assumption. We found that MEF RKIP+/+ + GFP-RKIP cells have
a slower rate of cell proliferation than MEF RKIP+/+ cells. However, some of MEF
RKIP+/+ cells expressing NLS deficient RKIP mutants have a higher rate of cell
proliferation than MEF RKIP+/+ cells, whereas some of them have the opposite effect.
Thus, we failed to see the nuclear localization of RKIP in MEF cell line plays a role in
regulating the cell proliferation process.
Previous studies have been conducted on cells that are over-expressing RKIP or have
knocked down the expression of RKIP. Recent studies have shown that RKIP depletion
regulates the transcription of proteins involved in both cell migration and proliferation
[128]. A few studies have gone so far as to completely remove RKIP from the mouse
embryonic fibroblasts (MEF) [130, 139]. These studies have shed valuable light on the
function of RKIP, and prompted us to see if we could determine whether RKIP had the
same effect when it is reintroduced in to cells lacking the gene for RKIP. We believe the
work on the cells lacking gene for RKIP is a complementary step to explain the cell
migration and proliferation result we found before. With this new method, we can clearly
see if RKIP is the main factor that plays an essential role in the regulation of cell motility
and growth. Moreover, downregulation of RKIP has been previously shown to promote
the activation of Raf-1 cascade in several cell lines. However, the modulation on Raf1/MEK/ERK pathway is ambiguous and still poorly understood. A few evidences so far
cannot prove that RKIP always has the regulatory function in inducing the activation of
Raf-1 signaling pathway. It is already known that different cell systems present different
results. Therefore, we can also use the mouse embryonic fibroblasts completely lacking
23

RKIP (MEF RKIP-/-) cell line to verify if RKIP has the same function on the activation
process of Raf-1/MEK/ERK signaling pathway.
Here we reported that RKIP promoted the rate of migration when we reintroduced RKIP
to MEF cells completely lacking RKIP. RKIP also inhibited proliferation in MEF cell
line. The effects that RKIP has on cell migration and proliferation could be linked to its
nuclear localization. We identified that GFP-RKIP expressing RKIP-/- cells had a
significantly lower number of cells in G2/M phase when compared to RKIP-/- cells. We
also found that RKIP had no effect on Raf activation in serum-stimulated cells.
2.2 Materials and Methods
Cell culture
Mouse embryonic fibroblasts (MEF) expressing RKIP (wild type RKIP+/+) and MEF
deficient in RKIP (homozygous RKIP-/-) were provided by Prof. Kam Yeung and
cultured in Dulbecco’s modified Eagles medium (DMEM) containing 10% fetal bovine
serum (FBS) in a humidified incubator at 37 oC with 5% CO2. Early passages of cells
cultured from frozen stock cultures were used in all experiments. Main cultures were
grown in 75cm2 tissue culture flasks with medium changed every two days. When the
cultures reached 90% confluence, the cells were gently washed twice with phosphate
buffered saline (PBS), and treated with a solution of trypsin/ ethylenediaminetetraacetic
acid (EDTA) in PBS to detach cells from the flasks. After cells were detached, an equal
volume of fresh medium was added to inhibit the trypsin activity. The cells were
resuspended in media and cell density was determined with a hemacytometer. Cells were
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replanted in fresh medium in new tissue culture flasks for continued culture and multiwell tissue culture plate for experiments.
Construction of stably transfected cell lines
Human RKIP was cloned in to the pEF6-myc-his B vector containing green fluorescent
protein (GFP; a kind gift of Prof. David Knecht) in cloned into its Eco RI and Eco RV
sites. The point mutants were constructed with the following primers:
R146N: 5'-AACCGATCTGGAGACCACAATGGCAAATTCAAGGTGGC-3' and 5'GCCACCTTGAATTTGCCATTGTGGTCTCCAGATCGGTT-3'
K148N: 5'-AGACCACCGTGGCAATTTCAAGGTGGCGTC-3' and 5'GACGCCACCTTGAAATTGCCACGGTGGTCT-3'
K150N: 5'-GACCACCGTGGCAAATTCAATGTGGCGTCCTT-3' and 5'AAGGACGCCACATTGAATTTGCCACGGTGGTC-3'
R146N, K148N, K150N: 5'CCGATCTGGAGACCACAATGGCAATTTCAATGTGGCGTCCTTCCGTA-3' and 5'GGCTAGACCTCTGGTGTTACCGTTAAAGTTACACCGCAGGAAGGCAT-3'
R155N: 5'-AATTCAAGGTGGCGTCCTTCAATAAAAAGTATGAGCTCAGGG-3' and
5'-CCCTGAGCTCATACTTTTTATTGAAGGACGCCACCTTGAATT-3'
K156N: 5'-GTGGCGTCCTTCCGTAATAAGTATGAGCTCAGGG-3' and 5'CCCTGAGCTCATACTTATTACGGAAGGACGCCAC-3'
K157N: 5'-GTGGCGTCCTTCCGTAAAAATTATGAGCTCAGGGC-3' and 5'GCCCTGAGCTCATAATTTTTACGGAAGGACGCCAC-3'
R155N, K156N, K157N: 5'AAATTCAAGGTGGCGTCCTTCAATAATAATTATGAGCTCAGGGCCCCGGTG-3'
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and 5'CACCGGGGCCCTGAGCTCATAATTATTATTGAAGGACGCCACCTTGAATTT-3'
R155N, K148N, K150N, R155N, K156N, K157N:
5'AATTTCAATGTGGCGTCCTTCAATAATAATTATGAGCTCAGGGCCCCGGGG3' and 5'CCCCGGGGCCCTGAGCTCATAATTATTATTGAAGGACGCCACATTGAAATT-3'
All GST-tagged rat RKIP (a kind gift of Prof. Kam Yeung) deletion mutant constructs
were cloned in the pEF6-GFP-Myc-His B vector in between the Eco RV and Not I sites
using the following primers:
GST fusion: 5’-ATAGCGCGCGATATCATGTCCCCTATACTAGG-3’ and 5’ATAGCGGCCGCTCACGATGAATAAGCTT-3’
Once sequenced, the vectors were transfected using Lipofectamine 2000.
The GFP-NLS fusion construct was created by PCR amplification of the NLS with the
following primers:
NLS fusion:5’-GCGCGCATAGAATTCTCGTGGCAAATTCAAG-3’ and 5’GCGCGCATAGATATCCTTTTTACGGAAGGACG-3’
The amplification product was then digested with Eco RI and Eco RV and ligated into the
pEF6-GFP-Myc-His B vector.
Once sequenced, the GFP tagged Human RKIP and RKIP mutant proteins vectors
described above were transfected in to MEF+/+ and MEF -/- cells with Lipofectamine 2000
(Invitrogen) and selections was performed with 10 µg/mL Blasticidin S (InvivoGen) for
three weeks. After selection the cells were cultured in DMEM containing 10% FBS with
10 µg/mL Blasticidin S.
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Wound closure assay
All of the MEF created were plated on to 24-well tissue culture plates at a density of
1x105 cells/mL and allowed to reach confluence. Once confluent the cells were treated
with 10 µg/mL Mitomycin C and wounded manually with a small 0.5-10 µL pipette tip.
After 3 hours the media was replaced with fresh DMEM and the experiment continued
until the wounds were completely closed. Digital images were acquired as soon as the
wounds were made and at 3, 6, 9, 12, and 24 hours post wounding. The open wound
areas were obtained using NIH Image J software and were subsequently plotted against
time using GraphPad Prism software [136].
Cell Proliferation
Cell proliferation was measured using the CCK-8 kit as described by Dojindo. MEF cells
(124µL of a 4x104 cells/mL in DMEM growth medium) were plated in to two 96-well
tissue culture plates and incubated at 37 oC for 24 hours. After 24 hours one plate was
treated with WST-8 (CCK-8; Dojindo) in order to determine cell density at the start of
the experiment. The parallel plate was treated with WST-8 48 hours later and compared
to the numbers generated from the first plate. A ratio of 48hr/24hr was obtained for each
MEF cell line generated and plotted using GraphPad Prism.
Cell cycle analysis
MEF were plated at a density of 2x106 cells/mL and allowed to adhere overnight. 24
hours later, the cells were washed three times with 1x Phosphate Buffered Solution (PBS)
and trypsinized for 30 minutes. The cells were pelleted by centrifugation at 1000 rpm for
3 minutes and washed three times with PBS. The cells were then resuspended in mL PBS
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and fixed by adding ice-cold ethanol drop-wise with vortexing to prevent aggregation.
The cell suspension was then incubated overnight at 4oC. Following the fixation process,
the cells were pelleted and washed 3 times and resuspended in PBS containing 0.1%
Triton X-100, 250 µg/mL RNAse and 50 µg/mL propidium iodide for 1 hour. Cell cycle
analysis was performed by flow cytometry (BD Calibur, BD Biosciences) and analyzed
using Cell Quest software.
Raf activation assay
MEFs were plated at 1x105 cells/mL in 6-well tissue culture plates and allowed to reach
confluence. Once confluent, the cells were serum starved for 48 and activation was
achieved by reintroducing FBS into their medium. After 30 mintues the cells were lysed
in 100µL 2x SDS sample buffer and scraped into a centrifuge tube. The samples were
boiled for 10 minutes and subsequently centrifuged at 15000 rpm for 10 minutes. After
centrifugation, the samples were subjected to SDS-PAGE and transfected to
polyvinyldifluoride membrane. ERK activation was determined using the rabbit anti
phospho p-44/42 MAPK antibody (Cell Signaling Technology). The primary antibody
was probed with a goat anti-rabbit HRP antibody (Santa Cruz Biotechnology) with
visualization by enhanced chemiluminescence.
Raf pull-down assay
Raf pull down assays were performed by plating MEFs at 2x105 cells /mL in 100 mm
dishes. The cells were allowed to adhere overnight and well lysed the following morning
using ice cold 1xPBS supplemented with protease inhibitors (sigma) and 0.25% Triton X100 for 30 minutes. The samples were then centrifuged at 15000 rpm to remove any
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insoluble debris and the GFP fusion proteins were pulled down by incubating an antiGFP (FL) antibody (Santa Cruz Biotechnology) for 3 hours followed by protein G
magnectic beads for 1 hour. The beads were pelleted by at 1000 rpm for 3 minutes and
washed 3 times with PBS. The pellets were resuspended in 100 µL 2x SDS sample buffer
and subjected to SDS PAGE. The samples were transferred to PVDF and probed with a
rabbit anti Raf-1 (C-12) antibody (SantaCruz Biotechnology). The Raf-1 antibody was
probed with a goat anti rabbit HRP antibody and visualized by enhanced
chemiluminescence.
2.3 Results
RKIP has no effect on cell migration
We have previously shown that RKIP expression de-regulates cell cell adhesion and that
cells treated with a RKIP inhibitor migrated at a slower rate in Madin-Darby canine
kidney cells [140]. To determine whether RKIP has any effect, positive or negative, on
cell migration in MEF cells, we reintroduced RKIP into MEF RKIP+/+ and MEF RKIP-/cells. The cells were treated with Mitomycin C (MMC) to eliminate the effect cell
division and proliferation would have on the rate of wound closure. Following treatment
the cells were scratch wounded with a sterile micropipette tip. The rate of migration was
measured as function of wound area plotted against time until the wound was 100%
closed (roughly 24 hours). Comparing the wound closure rate of MEF+/+ and that of
MEF+/+ GFP RKIP, we can see there is no visible differences between rates of migration
relevant to the amount of RKIP expression (Fig.1A). We can also draw a conclusion that
GFP introduced in MEF+/+ does not have any effect on cell migration (Appendix Fig.2).
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Therefore, we believe that RKIP is the only factor that controls the modulation of cell
migration. We then reintroduce RKIP to MEF RKIP-/- cells to see what role of RKIP can
play in cell migration. To our surprise, MEF-/- GFP RKIP has a dramatically higher rate
of migration than MEF-/- (Fig.1B). Although there is no obviously difference in the rates
of migration between MEF+/+ and MEF-/-, we can still find that MEF+/+ migrates very
slightly faster than MEF-/-. Therefore, these strong evidences reveal that RKIP has no
effect on cell migration of MEF cell line.

Fig. 1A Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP cells in the
presence of mitomycin C. we cannot see there is any visible difference between rates of
migration relevant to the amount of RKIP expression.
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Fig.1B Wound closure in MEF RKIP+/+, MEF RKIP-/- and MEF RKIP-/- GFP RKIP cells
in the presence of mitomycin C. MEF RKIP-/- GFP RKIP migrates dramatically faster
than MEF RKIP-/-. There is no obviously difference in the rates of migration between
MEF RKIP+/+ and MEF RKIP-/-, but we can still find that MEF RKIP+/+ migrates very
slightly faster than MEF RKIP-/-.
NLS of RKIP has a regulatory effect on cell migration
We have demonstrated that RKIP is able to promote cell migration in MEF cell line. To
determine whether or not NLS of RKIP expression has a regulatory effect on cell
migration, we reintroduced NLS deficient point mutants of RKIP, which are described in
construction of stably transfected cell lines of materials and methods part, into MEF
RKIP+/+ and MEF RKIP-/- cells. Although we have not collected the data for MEF RKIP/-

cells yet, we can still find an interesting result from the MEF RKIP+/+ cell migration

data. MEF RKIP+/+ GFP RKIP K148N has a positive effect on cell migration (Appendix
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Fig.6). However, MEF RKIP+/+ GFP RKIP R155N, MEF RKIP+/+ GFP RKIP K157N and
MEF RKIP+/+ GFP GST RKIP (1-134) have a negative effect on cell migration
(Appendix Fig. 8, 10 and 12). Moreover, we also found that MEF RKIP+/+ GFP RKIP
R146N, MEF RKIP+/+ GFP RKIP K150N, MEF RKIP+/+ GFP RKIP K156N MEF
RKIP+/+ GFP RKIP R146N K148N K150N, MEF RKIP+/+ GFP RKIP R155N K156N
K157N and MEF RKIP+/+ GFP GST RKIP showed no effect on cell migration (Appendix
Fig.3, 5, 7, 9, 11 and 13).
RKIP has a regulatory effect on cell proliferation
To determine whether or not RKIP expression had a regulatory effect on cell proliferation,
we plated MEF cells of the cells in 96-well tissue culture treated plates and measured
their proliferation over 24 hours with WST-8. Wild type MEF cells exhibited a slower
proliferation rate when compared to RKIP deficient RKIP-/- cells (Fig. 2A). Similarly,
RKIP-/- cells exhibited a faster rate of proliferation when compared to RKIP -/- cells reexpressing RKIP (Fig. 2B).
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Fig. 2A MEF cell proliferation is regulated by RKIP expression. Wild type MEF RKIP+/+
cells proliferate at a significantly slower rate when compared to MEF RKIP -/-.
NLS RKIP has a regulatory effect on cell proliferation
We have demonstrated that RKIP is able to reduce the rate of cell proliferation in MEF
cell line. To determine whether or not NLS of RKIP expression has a regulatory effect on
cell migration, we reintroduced NLS deficient point mutants of RKIP, which are
described in construction of stably transfected cell lines of materials and methods part,
into MEF RKIP-/- cells. Surprisingly, MEF RKIP-/- cells expressing RKIP missing the
NLS show the tendency to revert to the RKIP

-/-

proliferation rate (Fig. 2B). We can

clearly see that, except for MEF RKIP-/- GFP RKIP K150N, the rest of the MEF RKIP-/cells with NLS point mutants of RKIP expressed has the similar or higher rate of
proliferation than MEF RKIP-/- GFP RKIP cells. Therefore, there seems to be a regulatory
effect NLS of RKIP would have on the cell proliferation of MEF cell line.
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Fig. 2B MEF cell proliferation is regulated by RKIP expression. MEF RKIP-/- cells with
RKIP and various RKIP mutants proliferate at a slower rate much like wild type MEF
RKIP+/+ cells. Mutations located in the NLS or completely removing the NLS in the Cterminus of RKIP negatively affects the proliferative effect observed in MEF RKIP +/+
cells. Asterisks indicate statistical significance (p<0.05 compared to controls) derived
from three different experiments.
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RKIP expression regulates cell cycle distributions
To prove that RKIP expression alone was enough to regulate the cell cycle cultured cells
deficient in RKIP along with RKIP-/- with RKIP introduced. Following a 24-hour
incubation the cells were fixed and the cell cycle distribution was analyzed using flow
cytometry after staining with propidium iodide. Consistent with previous results, RKIP
expression coincided with a larger amount of cells in the apoptotic and G2/M phases
when compared to RKIP-/- cells expressing GFP (Fig. 3)

Fig. 3 Deletion of the C terminus of RKIP eliminates effect RKIP has on cell cycle
distributions in MEF RKIP-/- cells. Cell cycle analysis of unsynchronized MEF RKIP-/cells expressing RKIP showed increased apoptosis and a larger amount of cells in S phase
with a decrease in the amounts of cells in G2/M. MEF RKIP-/- cells expressing RKIP (1-
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134) reverted to MEF RKIP-/- profile. Asterisks indicate statistical significance (p<0.05
compared to controls) derived from three different experiments.
RKIP expression has no effect on Raf-1 activation in cells lacking serum stimulation
To determine whether a lack on nuclear accumulation resulted in decreased Raf-1 activity
we serum starved and stimulated our engineered cell lines to observe the effect. No
observable difference was detected after stimulation in all of engineered cell lines (Fig
4A). Interestingly, MEF-/- cells with RKIP NLS deficient mutants bound Raf but failed to
mitigate its activity in the presence of serum stimulation.

Fig. 4A RKIP expression in MEF cells fails to suppress ERK activity in the presence
of serum stimulation. Western blotting of p-ERK in MEF whole cell lystates after serum
starvation and subsequent stimulation with 10% serum. Experiment performed in in
triplicate. 1) MEF RKIP+/+, 2) MEF RKIP-/- 3) MEF RKIP-/- GFP, 4) MEF RKIP-/- GFPRKIP, 5) MEF RKIP-/- GFP-GST-RKIP, 6) MEF RKIP-/- GFP-GST-RKIP(1-134) and 7)
MEF RKIP-/- GFP-GST-RKIP(60-187).
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Fig. 4B RKIP expression in MEF cells fails to suppress ERK activity in the presence
of serum stimulation. Western blotting of Raf in MEF cells after coimmunoprecipitation of GFP. 1) MEF RKIP-/- GFP, 2) MEF RKIP-/- GFP-RKIP, 3) MEF
RKIP-/- GFP-RKIP (146-NGNFNVASFNNN-157), 4) MEF RKIP-/- GFP-GST-RKIP,
and 5) MEF RKIP-/- GFP-GST-RKIP(1-134).
2.4 Discussion
RKIP is a multifaceted protein that has been linked to tumor metastasis, cell migration,
and cell proliferation. However, a consensus on the role RKIP plays in these processes
has yet to be reached since different groups have seen different results. To study the
effect RKIP has we decided to study wild type MEF cells along with MEF cells
completely devoid of RKIP. We then reintroduced RKIP in to the cells lacking RKIP and
observed some of the more variable results published in the RKIP field.
RKIP has been shown to inhibit [128, 139, 143], promote [137, 140, 144, 162], and have
no effect [162] on cell migration. These seemingly contradictory results could depend on
the migration analysis method in question. For example, some groups favor a larger
wound and measure the time needed for the cells to fill in the gap created by the
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wounding mechanism. Although this method is a valid way to measure migration, a
larger wound takes longer to close allowing for cell division to take place during the
healing process. The cell line used could also explain the seemingly variable results.
Some cell lines migrate faster, making any role RKIP has in the process harder to
measure. In addition, knockdowns do not completely eliminate the protein in question
and some of the error could be due to remaining RKIP activity. To address these issues,
we used MEF+/+, MEF-/-, MEF+/+ +GFP-RKIP and MEF-/- +GFP-RKIP cells to conduct
the experiment. We also made small wounds that would lessen the effect cell division
would have on the migration process. Considering there is still a remaining effect cell
division in the wound healing process, we then treated the cells with MMC to eliminate
this negative effect. We noticed that MMC did significantly slow the rate of cell
migration (Appendix Fig.1). The data we have collected reveals that RKIP has no effect
on the cell migration (Fig. 1). Furthermore, we found that MEF RKIP+/+ GFP RKIP with
NLS deficient point mutants of RKIP expressed have a variety of regulatory effects on
cell migration. The different results exhibited that they have positive, negative, and
neutral effects on cell migration (Appendix Fig.5-13). The reason for these conflicting
results is difficult to explain. But, in my opinion, NLS of RKIP still seems to have a
regulatory function on cell migration. Perhaps some of the mutants do not affect RKIP
binding to importin α and its translocation to nucleus in which RKIP plays a role in
modulating the protein expression involved in cell migration process. The mutants that
showed the opposite regulatory effect on cell migration can be accounted for the
substitution of the amino acids on NLS disrupting the binding between RKIP and
importin α preventing RKIP from being transported into nucleus. Without the regulation
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of protein expression involved in cell migration process by RKIP, the cells exhibit a
lower rate of cell migration.
Another biological process that seems to vary depending on the cell type is cell
proliferation. A few groups have not seen any link between RKIP and cell proliferation
[146, 147, 156], while the remainder of the studies have noticed a negative effect on
proliferation [130, 143, 144, 163]. When comparing wild type MEF cells with RKIP
deficient MEF cells we noticed that the cells expressing RKIP were proliferating at a
higher rate (Fig. 2A). We then introduced GFP and GFP-RKIP into MEF RKIP-/- cells
and confirmed the role RKIP plays in reducing cell proliferation (Fig. 2B). Moreover, we
transfected cells lacking RKIP with GFP-RKIP NLS point mutants and RKIP deletion
mutants [121]. Interestingly, we found that RKIP 146-NGNFNVASFNNN-157 failed to
reduce the cell proliferation as MEF RKIP-/- GFP-RKIP did. However, MEF RKIP-/GFP-RKIP with single amino acid substitutions on NLS of RKIP still have the same
regulatory effect on cell proliferation with MEF RKIP-/- GFP-RKIP. Furthermore, GFPGST-RKIP and GFP-GST-RKIP (60-187) exhibited regulation of proliferation while the
GFP-GST-RKIP (1-134) reverted to the RKIP deficient proliferation profile. These
results suggest that nuclear localization is necessary for RKIP to reduce cell proliferation.
Although the mechanism that nuclear localization of RKIP regulates the cell proliferation
remains ambiguous, in my opinion, it can be explained with the similar reason that I
described above in the discussion part for cell migration. Cell proliferation of MEF cell
line may be regulated only when RKIP goes into the nucleus and modulates the gene
expression involved in cell proliferation process.
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It has been reported that phosphorylation of RKIP causes dissociation of Raf [123] and
association with centrosomes and kinetochores [130]. The authors found that RKIP
delepleted cells had lower Aurora B kinase activity [130], and they reasoned that RKIP
depleted cells could override spindle checkpoints ultimately accelerating the cell cycle
progression. To determine whether the effect on proliferation could be linked to cell cycle
progression, we used the mutants that seemed to have the most detrimental effect and
study the cell distribution by flow cytometry. Consistent with previous results [128, 133,
135, 164], RKIP seems to increase apoptosis and promote a shift of cell distribution in
the S phase (Fig. 3). The authors reasoned that RKIP regulates a checkpoint in G2 that
cells are required to go through in order to enter M phase. Absence of RKIP allows the
cells to skip this checkpoint and proliferate at a higher rate.
RKIP was first initially found to disrupt the interaction between Raf and MEK
subsequently preventing the activation of MAPK/ERK pathway [120]. The MAPK/ERK
pathway has been previously implicated in cell cycle progression [165-170].

To

determine whether the regulatory effect RKIP seems to have in MEF cells was directly
related to Raf activation, we serum starved confluent cells for 48 hours and then
stimulated the cells with the addition of 10% FBS. Both wild type and RKIP depleted
MEF

cells

responded

to

the

stimulus.

The

GFP-RKIP

and

GFP-RKIP

NGNFNVASFNNN expressing cells also exhibited normal Raf activation (Fig. 4A).
Interestingly, and the GFP-GST-RKIP (1-134) mutant lacking the serine 153
phosphorylation site still exhibited Raf activation in the presence of serum. This result
could imply that a different method of regulation is available or that the protein is
inactive (Fig. 4B). To determine whether the C terminus deletion mutant was active we
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performed pull down experiments for RKIP full length and C terminus deletion mutants.
We found that RKIP and the RKIP deletion mutant associated with Raf, consistent with
previous results [121]. Taken together, these results indicate that nuclear localization is
required for the role regulatory role RKIP plays in both cell migration and cell
proliferation. In addition, these regulatory activities are independent of Raf-1/MEK/ERK
signaling pathway. Furthermore, these results also reveal that there may be a new
signaling pathway in which RKIP has the regulatory function on cell migration and
proliferation of MEF cell line. To discover what pathway it is, more work needs to be
done in the future. However, what we know is that RKIP modulates a variety of
processes in a large number of cell lines. Conflicting results can be attributed to both
different cell lines and different methods used to manipulate RKIP expression.
In summary, we discovered that RKIP has no effect on the rate of migration of MEF cell
line. RKIP also inhibited proliferation in MEF cell line. The effects that RKIP has on cell
migration and proliferation could be linked to its nuclear localization. We did notice an
increase in the amount of cells in apoptosis and S phase by flow cytometry in cells
expressing RKIP, but not cells expressing RKIP without a NLS. We also confirmed that
Raf activity was not the reason that RKIP reduced cell proliferation.
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APPENDIX

Fig.1 Mitomycin C can eliminate effect cell division and proliferation have on the rate of
cell migration. We can obviously see MEF RKIP+/+ with mitomycin C treated
migrates significantly slower than MEF RKIP+/+ without mitomycin C treated.

Fig.2 GFP introduced into MEF RKIP+/+ does not have any effect on cell migration. MEF
RKIP+/+ GFP has almost the same rate of cell migration with MEF RKIP+/+.
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Fig.3 GFP GST introduced into MEF RKIP+/+ does not have any effect on cell migration.
MEF RKIP+/+ GFP GST has almost the same rate of cell migration with MEF
RKIP+/+.

Fig.4 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP cells in the presence
of mitomycin C.
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Fig.5 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP R146N cells in the
presence of mitomycin C.

Fig.6 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP K148N cells in the
presence of mitomycin C.
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Fig.7 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP K150N cells in the
presence of mitomycin C.

Fig.8 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP R155N cells in the
presence of mitomycin C.
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Fig.9 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP K156N cells in the
presence of mitomycin C.

Fig.10 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP K157N cells in the
presence of mitomycin C.
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Fig.11 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP (R146N, K148N,
K150N) cells in the presence of mitomycin C.

Fig.12 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP GST RKIP (1-134) cells
in the presence of mitomycin C.

47

Fig.13 Wound closure in MEF RKIP+/+ and MEF RKIP+/+ GFP RKIP (R155N, K156N,
K157N) cells in the presence of mitomycin C.
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